5-[7-(4-acetylpiperazin-1-yl)-2-(4-fluorophenyl)pyrazolo[1,5-c]pyrimidin-3-yl]-1,3-dihydroindol-2-one
C26H23FN6O2 — CID 122656081
Data last refreshed: (MolForge compound catalog, from PubChem)
About 5-[7-(4-acetylpiperazin-1-yl)-2-(4-fluorophenyl)pyrazolo[1,5-c]pyrimidin-3-yl]-1,3-dihydroindol-2-one
5-[7-(4-acetylpiperazin-1-yl)-2-(4-fluorophenyl)pyrazolo[1,5-c]pyrimidin-3-yl]-1,3-dihydroindol-2-one (PubChem CID 122656081) has the molecular formula C26H23FN6O2 and a molecular weight of 470.51 g/mol. Its IUPAC name is 5-[7-(4-acetylpiperazin-1-yl)-2-(4-fluorophenyl)pyrazolo[1,5-c]pyrimidin-3-yl]-1,3-dihydroindol-2-one.
Molecular Properties
| Compound Name | 5-[7-(4-acetylpiperazin-1-yl)-2-(4-fluorophenyl)pyrazolo[1,5-c]pyrimidin-3-yl]-1,3-dihydroindol-2-one |
|---|---|
| PubChem CID | 122656081 |
| Molecular Formula | C26H23FN6O2 |
| Molecular Weight | 470.51 g/mol |
| Exact Mass | 470.19 |
| IUPAC Name | 5-[7-(4-acetylpiperazin-1-yl)-2-(4-fluorophenyl)pyrazolo[1,5-c]pyrimidin-3-yl]-1,3-dihydroindol-2-one |
| SMILES | CC(=O)N1CCN(c2nccc3c(-c4ccc5c(c4)CC(=O)N5)c(-c4ccc(F)cc4)nn23)CC1 |
| InChI | InChI=1S/C26H23FN6O2/c1-16(34)31-10-12-32(13-11-31)26-28-9-8-22-24(18-4-7-21-19(14-18)15-23(35)29-21)25(30-33(22)26)17-2-5-20(27)6-3-17/h2-9,14H,10-13,15H2,1H3,(H,29,35) |
| InChIKey | UERCDXIHPYCAMF-UHFFFAOYSA-N |
| XLogP | 3.37 |
| TPSA | 82.84 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 3 |
| Heavy Atoms | 35 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 470.51 |
| LogP ≤ 5 | 3.37 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 6 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 122656081 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.